Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 25, 2024 16:05 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements

Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company...
June 04, 2024 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting

Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and...
June 03, 2024 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
May 09, 2024 16:05 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
May 08, 2024 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...
May 07, 2024 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference

BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...
April 24, 2024 10:01 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...
April 08, 2024 16:05 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...
April 02, 2024 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Host Business Update Call and Webcast

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...
February 29, 2024 10:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...